ABEO
Abeona Therapeutics Inc. · NASDAQ · Healthcare · USD · 10-K for 2025, filed 2026-03-17
Figures on this page computed 2026-11-08 12:40 UTC
Last close
3.91USD
Market data, 2026-11-05
Except where said otherwise: 10-K for 2025, filed 2026-03-17
3.1xP/E
Price / Earnings per Share (diluted)
- Source
- computed
- Fiscal year
- 2025
- Accession
- 0001493152-26-010413
- Reported in
- USD
- computed
- 10-K for 2025, filed 2026-03-17
-84.5%ROIC
NOPAT / Invested Capital x 100, where NOPAT = Operating Income x (1 - Tax Rate) and Invested Capital = Equity + Total Debt - Cash
- Source
- computed
- Fiscal year
- 2025
- Accession
- 0001493152-26-010413
- Reported in
- USD
- 10-K for 2025, filed 2026-03-17
- 10-K for 2025, filed 2026-03-17
- 10-K for 2025, filed 2026-03-17
- 10-Q for 2025, filed 2026-08-13
- 10-K for 2025, filed 2026-03-17
- 10-Q for 2025, filed 2026-08-13
n/mNet marginnet income exceeds revenue
Net income exceeds revenue.
Net Income / Revenue x 100
- Source
- computed
- Fiscal year
- 2025
- Accession
- 0001493152-26-010413
- Reported in
- USD
- 10-K for 2025, filed 2026-03-17
- 10-K for 2025, filed 2026-03-17
-1448.5%FCF margin
Free Cash Flow / Revenue x 100
- Source
- computed
- Fiscal year
- 2025
- Accession
- 0001493152-26-010413
- Reported in
- USD
- 10-K for 2025, filed 2026-03-17
- 10-K for 2025, filed 2026-03-17
0.16Debt/equity
Total Debt / Shareholders' Equity
- Source
- computed
- Fiscal year
- 2025
- Accession
- 0001493152-26-010413
- Reported in
- USD
- 10-K for 2025, filed 2026-03-17
- 10-Q for 2025, filed 2026-08-13
n/aDividend yield
We do not hold this figure for this company, so there is nothing to place.
- Source
- computed
- Taken on
- 2026-11-07
- Reported in
- USD
- computed
Margins is the furthest below its sector's middle: 0.32 against 0.41 on the market's range.
- Growth-10.3%50 of 100, at its sector
- Returns on capital-84.5%66 of 100, above its sector
- Margins73.7%32 of 100, below its sector
- Price3.1x50 of 100, above its sector
- Safety0.1660 of 100, above its sector
- What it pays outn/anot placed
- What it pays out: n/aWe do not hold this figure for this company, so there is nothing to place.
Against its rival
lens 4 of 9Measure by measure
behind on 1 of 1- Profit on each unit of salesn/a-2,299%n/a
Higher is better here.
- Return on the capital it uses-84.5%n/an/a
Higher is better here.
- Sales growth over five years-10.3%n/an/a
Higher is better here.
- Debt against equity0.160.04Behind
Lower is better here.
- Gross margin73.7%n/an/a
Higher is better here.
- Price against earnings3.1xn/an/a
Lower is better here.
The first column is this company and the second is the one it is set against. A measure only one of the two reports is left at n/a rather than counted as a win.
Against CAMP4 Therapeutics Corporation, ABEO is behind on 1 of 1 measures.
Against CAMP4 Therapeutics Corporation, ABEO is behind on 1 of 1 measures.
Every figure in this lens
Except where said otherwise: 10-K for 2025, filed 2026-03-17
Profit on each unit of salesn/mnet income exceeds revenue
Net income exceeds revenue.
- Source
- filed
- Statement
- income
- Fiscal year
- 2025
- Accession
- 0001493152-26-010413
- Reported in
- USD
Return on the capital it uses-84.5%
- Source
- filed
- Statement
- income
- Fiscal year
- 2025
- Accession
- 0001493152-26-010413
- Reported in
- USD
Sales growth over five years-10.3%
- Source
- filed
- Statement
- income
- Fiscal year
- 2025
- Accession
- 0001493152-26-010413
- Reported in
- USD
Debt against equity0.16
- Source
- filed
- Statement
- income
- Fiscal year
- 2025
- Accession
- 0001493152-26-010413
- Reported in
- USD
Gross margin73.7%
- Source
- filed
- Statement
- income
- Fiscal year
- 2025
- Accession
- 0001493152-26-010413
- Reported in
- USD
Price against earnings3.1x
- Source
- filed
- Statement
- income
- Fiscal year
- 2025
- Accession
- 0001493152-26-010413
- Reported in
- USD